The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach

被引：12

作者：

Allen, Joanne V. ^{[1
]}

Bardelle, Catherine ^{[1
]}

Blades, Kevin ^{[1
]}

Buttar, Dave ^{[1
]}

Chapman, Louise ^{[1
]}

Colclough, Nicola ^{[1
]}

Dossetter, Alexander G. ^{[1
]}

Garner, Andrew P. ^{[1
]}

Girdwood, Alan ^{[1
]}

Lambert, Christine ^{[1
]}

Leach, Andrew G. ^{[1
]}

Law, Brian ^{[1
]}

Major, John ^{[1
]}

Plant, Helen ^{[1
]}

Slater, Anthony M. ^{[1
]}

机构：

[1] AstraZeneca R&D, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 18期

关键词：

c-Met; Kinase; Directed screening; Ligand efficiency; Secondary metabolism; Bio-isosteres; Decisions; Benzanilides; SMALL-MOLECULE INHIBITOR; IN-VIVO; GROWTH; 3-CARBOXY-BETA-CARBOLINES; PROTOONCOGENE; OPTIMIZATION; DERIVATIVES; ACTIVATION; POTENT; GAB1;

D O I：

10.1016/j.bmcl.2011.07.047

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A directed screen of a relatively small number of compounds, selected for kinase ATP pocket binding potential, yielded a novel series of hit compounds (1). Hit explosion on two binding residues identified compounds 27 and 43 as the best leads for an optimization program having reduced secondary metabolism, as measured by in vitro rat hepatocytes incubation, leading to oral bio-availability. Structure-activity relationships and molecular modeling have suggested a binding mode for the most potent inhibitor 12. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：5224 / 5229

页数：6

共 50 条

[1] Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening
Lemcke, Thomas
Dreher, Jan
Rarey, Matthias
Totzke, Frank
Schaechtele, Christoph
Kubbutat, Michael H. G.
Kunick, Conrad
MOLECULAR INFORMATICS, 2011, 30 (2-3) : 145 - 150
[2] In vivo imaging of c-Met receptor tyrosine kinase using c-Met binding peptide
Kim, Eun-Mi
Park, Eun-Hye
Lee, Chang-Moon
Cheong, Su-Jin
Kim, Dong-Wook
Lim, Seok Tae
Sohn, Myung-Hee
JOURNAL OF NUCLEAR MEDICINE, 2009, 50
[3] Discovery of c-Met kinase inhibitors for anticancer therapeutics.
Yun, Chang-Soo
Cho, Sung Yun
Kim, Hyoung Rae
Jung, Hee Jung
Ha, Jae D.
Lee, Kwangho
Kim, Pilho
Park, Chi Hoon
Lee, Chong Ock
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[4] Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase
Porter, John
Lumb, Simon
Lecomte, Fabien
Reuberson, James
Foley, Anne
Calmiano, Mark
le Riche, Kelly
Edwards, Helen
Delgado, Jean
Franklin, Richard J.
Gascon-Simorte, Jose M.
Maloney, Alison
Meier, Christoph
Batchelor, Mark
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (02) : 397 - 400
[5] TYROSINE KINASE RECEPTOR INDISTINGUISHABLE FROM THE C-MET PROTEIN
GIORDANO, S
PONZETTO, C
DIRENZO, MF
COOPER, CS
COMOGLIO, PM
NATURE, 1989, 339 (6220) : 155 - 156
[6] Role of c-Met receptor tyrosine kinase in lung cancer
Ma, PC
Ramasamy, J
Seiwert, T
Tretiakova, MS
Husain, AN
Puri, N
Salgia, R
LUNG CANCER, 2004, 46 : S8 - S9
[7] Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration
Kim, Jung-Woo
Lee, Mi Nam
Jeong, Byung-Chul
Oh, Sin-Hye
Kook, Min-Suk
Koh, Jeong-Tae
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 806 : 10 - 17
[8] Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
Lucia Demkova
Lucia Kucerova
Molecular Cancer, 17
[9] Mechanism of resistance to c-Met tyrosine kinase inhibitors in human melanoma
Etnyre, Deven
Fong, Jason
Bertram, Ceyda
Puri, Neelu
CANCER RESEARCH, 2012, 72
[10] Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
Demkova, Lucia
Kucerova, Lucia
MOLECULAR CANCER, 2018, 17

← 1 2 3 4 5 →